Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.
Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. Hideshima T, et al. Among authors: cottini f. Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12. Blood. 2017. PMID: 28082445 Free PMC article.
Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM, Yucebay F, Zhao Q, Umyarova E, Cottini F, Bumma N, Rosko A, Benson D, Sharma N, Efebera Y, Devarakonda S. Khan AM, et al. Among authors: cottini f. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):e85-e96. doi: 10.1016/j.clml.2022.10.004. Epub 2022 Oct 27. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36411211
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Cea M, et al. Among authors: cottini f. Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5. Blood. 2012. PMID: 22955917 Free PMC article.
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N. Cirstea D, et al. Among authors: cottini f. Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28. Leukemia. 2013. PMID: 23807770 Free PMC article.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Minami J, et al. Among authors: cottini f. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5. Leukemia. 2014. PMID: 23913134 Free PMC article.
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G. Cottini F, et al. Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11. Nat Med. 2014. PMID: 24813251 Free PMC article.
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Mimura N, et al. Among authors: cottini f. Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16. Cancer Res. 2014. PMID: 24934808 Free PMC article.
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Suzuki R, et al. Among authors: cottini f. Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. Leukemia. 2015. PMID: 25306900 Free PMC article. No abstract available.
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC. Kikuchi S, et al. Among authors: cottini f. Leukemia. 2015 Sep;29(9):1918-27. doi: 10.1038/leu.2015.83. Epub 2015 Mar 24. Leukemia. 2015. PMID: 25801913
52 results